FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileEikon Therapeutics, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
EIKN
Eikon Therapeutics, Inc. Common Stock Stock AnalysisComprehensive stock analysis for Eikon Therapeutics, Inc. Common Stock (EIKN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisEIKN
EIKN
Eikon Therapeutics, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
EIKN
  1. Home
  2. Stocks
  3. Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock

🇺🇸EIKN•NASDAQ

Eikon Therapeutics, Inc. Common Stock

🇺🇸EIKN•NASDAQ
Market cap
$256.62M

Your view on EIKN

Mkt Cap
$256.62M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Eikon Therapeutics, Inc. Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Roger Perlmutter
Headquarters
230 Harriet Tubman Way, Millbrae, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Roger Perlmutter
Headquarters
230 Harriet Tubman Way, Millbrae, CA, US
Description

Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs.

It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells.

Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers.

Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Eikon Therapeutics, Inc. Common Stock. Starting points for Eikon Therapeutics, Inc. Common Stock: EPS -$6.22, beta 0.94 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Eikon Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Eikon Therapeutics, Inc. Common Stock stands at -$6.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Eikon Therapeutics, Inc. Common Stock. Eikon Therapeutics, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold EIKN19 companies · 8 funds
Compare EIKN with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ARVNArvinas, Inc.HealthcareBiotechnology$423.0M
BBOTBridgeBio Oncology Therapeutics Inc.HealthcareBiotechnology$145.3M
KZIAKazia Therapeutics LimitedHealthcareBiotechnology$8.0M
NVCTNuvectis Pharma, Inc.HealthcareBiotechnology$666.8M
ORICORIC Pharmaceuticals, Inc.HealthcareBiotechnology$764.9M
PRLDPrelude Therapeutics IncorporatedHealthcareBiotechnology$187.0M
TPSTTempest Therapeutics, Inc.HealthcareBiotechnology$5.7M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
SCPXScorpius Holdings, Inc.HealthcareOTC$130,071
SCTXScribe Therapeutics Inc.HealthcareNASDAQ$195.3M
SEERSeer, Inc.HealthcareNASDAQ$75.9M
SEOVFSernova Corp.HealthcareOTC$33.7M
SEPNSepterna, Inc.HealthcareNASDAQ$1.8B
SEPSFAsep Medical Holdings IncHealthcareOTC$121,249
SERSerina Therapeutics, Inc.HealthcareAMEX$16.8M
SGMOQSangamo Therapeutics, Inc.HealthcareOTC—
SGMTSagimet Biosciences Inc.HealthcareNASDAQ$648.0M
SGPSpyGlass Pharma, Inc. Common StockHealthcareNASDAQ$1.0B
SHJBFShanghai Junshi Biosciences Co., Ltd.HealthcareOTC$4.1B
SIGYSigyn Therapeutics, Inc.HealthcareOTC—
ETFs holding Eikon Therapeutics, Inc. Common Stock
TickerFundFund assets% of the fund
IWMiShares Russell 2000 ETF$76.6B in assets0.01%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.00%
IWOiShares Russell 2000 Growth ETF$13.7B in assets0.01%
TINYProShares - Nanotechnology ETF$11M in assets0.64%
SBIOALPS Medical Breakthroughs ETF$187M in assets0.18%
OMFSInvesco Russell 2000 Dynamic Multifactor ETF$267M in assets0.07%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.01%

Largest holders first, then the funds most concentrated in EIKN.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Eikon Therapeutics, Inc. Common Stock, and how their positions are changing. At a $256.6M market value, institutional positions materially move Eikon Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Eikon Therapeutics, Inc. Common Stock executives and directors. Shares of Eikon Therapeutics, Inc. Common Stock have traded between $7.90 and $17.40 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Eikon Therapeutics, Inc. Common Stock. Coverage tracks Eikon Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Eikon Therapeutics, Inc. Common Stock.

EIKN AnalysisWeak
Past
1
Growth
2
Health
3
Profit
1
Value
1